Guillen OFC, Díaz BA

Language: Spanish
References: 8
Page: 251-254
PDF size: 546.14 Kb.

ABSTRACT

Introduction: venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is influenced by hereditary and acquired risk factors. Among the acquired factors, obesity, advanced age, and acute illnesses requiring hospitalization increase the predisposition to VTE. In patients with acute non-surgical medical conditions, thromboprophylaxis is underutilized, despite the existence of the internationally validated Padua scale, which assesses VTE risk and guides the implementation of mechanical or pharmacological prophylaxis. Objective: to determine the percentage of non-surgical patients at Hospital Angeles Lomas, at high risk of VTE according to the Padua scale, who received thromboprophylaxis. Material and methods: observational, cross-sectional, and retrospective study. Patients hospitalized for more than 48 hours due to acute non-surgical medical conditions between October 2022 and March 2023 were included. A non-probabilistic sampling method was used, and medical records were reviewed. A Padua score > 4 indicated high VTE risk, and prophylaxis administration was assessed. Results: of 214 patients, 28.9% had a Padua score > 4, of whom 96.77% received thromboprophylaxis. Conclusions: patients at high risk of venous thromboembolism according to the Padua score received thromboprophylaxis at a high percentage (96.77%). These results reflect adequate adherence to prophylaxis recommendations in this population.

REFERENCES

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. N Engl J Med. 2019; 380 (12): 1139-1149.

2. Spyropoulos AC, Ageno W, Cohen AT, Gibson CM, Goldhaber SZ, Raskob G. Prevention of venous thromboembolism in hospitalized medically ill patients: a U.S. perspective. Thromb Haemost. 2020; 120 (6): 924-936.

3. Cabrera-Rayo A, Nellen-Hummel H. Epidemiología de la enfermedad tromboembólica venosa. Gac Med Mex. 2007; 143 (Suppl: 1): 3-5.

4. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008; 371 (9610): 387-394.

5. Schünemann HJ, Cushman M, Burnett AE et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2 (22): 3198-3225. Blood Adv. 2023; 7 (9): 1671.

6. Cabrera-Rayo A, Hernández-Díaz EJ, Guzmán-Rosales G, Laguna-Hernández G, Pliego-Reyes C, Zendejas-Villanueva JL et al. Tromboprofilaxis en pacientes médicos y quirúrgicos: resultados de un estudio multicéntrico realizado en hospitales de la Ciudad de México. Med Int Méx. 2017; 33 (6): 746-753. doi: 10.24245/mim.v33i6.1461.

7. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8 (11): 2450-2457.

8. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75 (23): 2950-2973.